US Equities insigtX

Cerenome Announces Interim Data from Repeat-Dosing REYOBIQ in Leptomeningeal Metastasis

HOUSTON, November 16, 2026 -- Cerenome, Inc., a central nervous system oncology company advancing an integrated platform combining precision diagnostics, targeted radiopharmaceuticals, and artificial intelligence, today announced interim…

Published
Market
US Equities
Source
insigtX

HOUSTON, November 16, 2026 -- Cerenome, Inc., a central nervous system oncology company advancing an integrated platform combining precision diagnostics, targeted radiopharmaceuticals, and artificial intelligence, today announced interim data from its ongoing ReSPECT-LM study evaluating repeat intracerebroventricular dosing of REYOBIQ™ in patients with leptomeningeal metastasis (LM). The data were presented in a poster on November 13, 2026, at the Society for Neuro-Oncology 31st Annual Meeting and Education Day. The poster reported treatment exposure, safety, dosimetry, LM progression status, and CSF tumor cell findings from the first 10 treated patients. No dose-limiting toxicities or adverse events leading to treatment discontinuation were reported. To date, one patient has received three doses of 26.4 mCi, for a total administered activity of 79.2 mCi. This exceeds the highest single-dose activity administered in the prior single-dose ReSPECT-LM study. Additionally, imaging showed consistent radiation doses delivered to the LM compartment across treatments in each patient, with a median difference of 8%. These levels are consistent with previously reported Phase 1 single-dose data. Dose escalation is ongoing.

Among evaluable patients, no LM progression was recorded at the three- and six-month time points, and progression was recorded in 1 of 4 evaluable patients at nine months.

"These interim findings support the feasibility and early tolerability of fractionated REYOBIQ dosing as an approach to delivering higher cumulative radiation doses to the LM compartment," said Eric J. Daniels, M.D., Chief Operating Officer of Cerenome. "The LM progression findings among evaluable patients are encouraging, with no dose-limiting toxicities to date and consistent radiation delivery across repeat doses. Our focus now is on continuing dose escalation and enrollment to determine the recommended multi-dose regimen to support a future randomized study."

ReSPECT-LM Interim Findings

Among the 10 patients, 6 received 13.2 mCi per dose and 4 received 26.4 mCi per dose. Primary cancers included melanoma, breast cancer, non-small cell lung cancer, ovarian cancer, and neuroendocrine carcinoma. Nine patients had received prior LM treatment, and 3 were receiving concurrent systemic therapy.

Safety: No dose-limiting toxicities or adverse events leading to discontinuation were observed. One patient experienced Grade 3 treatment-related nausea that resolved within five days. The only serious adverse event was shortness of breath in one subject, considered unrelated to treatment. All 10 patients experienced at least one treatment-emergent adverse event; the most common were nausea, headache, decreased lymphocyte count, and decreased white blood cell count.

Time-point LM progression findings: Among evaluable patients, no LM progression was recorded at three or six months. At nine months, LM progression was recorded in 1 of 4 evaluable patients. Evaluability was determined by the principal investigator based on available record review, defined by documented progression at or before the time point, or sufficient disease assessment follow-up establishing LM status through that time point. Patients with insufficient follow-up or who died of primary disease before the time point without prior LM progression were excluded. These descriptive findings are not progression-free survival estimates.

CSF tumor cell findings: Serial monitoring with Cerenome's CNSide® recorded tumor cell reductions in individual patients. Three patients with detectable tumor cells at baseline later showed zero tumor cells/mL in samples. Two of these remained at zero tumor cells/mL at their most recent assessments, at 9.2 months and 2.3 months from first dose, respectively. The third patient later showed a rise in tumor cell count and had MRI-confirmed LM progression nearly 4 months after the third REYOBIQ dose.

High cumulative absorbed dose: The first patient to complete three doses of 26.4 mCi per dose had an estimated cumulative LM compartment absorbed dose of 207 Gy, with no dose-limiting toxicity. Five patients who completed three doses at the lowest dose level had cumulative LM compartment absorbed doses of 85–137 Gy, also consistent with previously observed Phase 1 data.

Consistent repeat-dose delivery: Among patients receiving repeat doses, there was minimal variation in absorbed dose per unit mCi across doses, as well as in CSF effective half-life. Dosimetry was consistent with the prior single-dose ReSPECT-LM experience, supporting the feasibility of repeat dosing. SPECT/CT imaging in the patient who completed three 26.4 mCi doses showed similar activity distribution after each dose.

Low estimated bone marrow exposure: The median blood-derived bone marrow absorbed dose was 0.023 Gy per dose. This low level of blood exposure is important for avoiding potential cytopenias and further supports continued investigation of localized LM compartment delivery.

"Among evaluable patients, no LM progression was recorded at the three- and six-month time points, which is early and encouraging, particularly in a population where most patients had received prior LM treatment," said Andrew J. Brenner, M.D., Ph.D., Professor of Medicine at UT Health San Antonio Mays Cancer Center and first author of the poster. "The ability to deliver substantial cumulative radiation doses with consistent repeat-dose delivery and low estimated bone marrow exposure supports further evaluation. These findings remain preliminary and require continued enrollment and follow-up to determine the clinical activity of this regimen."

These preliminary findings are from an ongoing open-label dose-escalation study. Patients had varied primary cancers, treatment histories, and follow-up durations, and some received concurrent systemic therapy. Time-point analyses included only patients evaluable at each time point and did not establish progression-free or overall survival benefit. As previously announced, Cerenome plans to conduct a Phase 2 randomized study in 2027, subject to continued clinical progress and regulatory alignment.

Poster Presentation

Abstract Code: CTNI-40

Poster Title: Repeat Intracerebroventricular Rhenium-186 Obisbemeda in Leptomeningeal Metastasis: Interim Dosimetry, Safety, and CSF Tumor Cell Response from the ReSPECT-LM Multiple-Dose Study

Date and Time: Friday, November 13, 2026, 7:30–9:30 PM ET

Location: Exhibit Hall D&E, Pennsylvania Convention Center, Philadelphia

Forward-Looking Statements

This press release contains statements that may be considered "forward-looking statements" within the meaning of U.S. securities laws, including statements regarding commercialization, clinical trials, and future developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future-tense verbs and terms such as "anticipate," "plan," "future," "goal," "continue," and similar expressions or their negatives. Such statements are based on certain assumptions and evaluations made by management based on their experience and their perception of historical trends, current conditions, expected future developments, and other factors they believe are appropriate. These statements include, but are not limited to, statements regarding the development and clinical utility of the ReSPECT-LM study and future randomized studies regarding ReSPECT-LM.

Original: https://www.globenewswire.com/news-release/2026/11/16/3403396/0/en/cerenome-reports-interim-respect-lm-data-supporting-repeat-dosing-of-reyobiq-in-leptomeningeal-metastases-at-the-2026-sno-annual-meeting.html

insigtX content is informational and educational, not investment advice.